Abbonarsi

Early-phase dose articulation trials are underutilized for post-stroke motor recovery: A systematic scoping review - 09/02/22

Doi : 10.1016/j.rehab.2021.101487 
Emily J. Dalton a, Leonid Churilov b, Natasha A. Lannin c, d, Dale Corbett e, Bruce C.V. Campbell f, Kathryn S. Hayward g,
a Melbourne School of Health Sciences, University of Melbourne, Heidelberg, Australia 
b Melbourne Medical School, University of Melbourne, Parkville, Australia 
c Department of Neurosciences, Central Clinical School, Monash University, Melbourne, Australia 
d Alfred Health, Melbourne, Australia 
e Cellular & Molecular Medicine and Canadian Partnership for Stroke Recovery, University of Ottawa, Canada 
f Department of Medicine and Neurology, Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia 
g Melbourne School of Health Sciences and Florey Institute of Neuroscience and Mental Health, University of Melbourne, 245 Burgundy Street, 3084 Heidelberg, Australia 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

To enable development of effective interventions, there is a need to complete systematic early-phase dose articulation research. This scoping review aimed to synthesize dose articulation research of behavioral motor interventions for stroke recovery.

Methods

MEDLINE and EMBASE were systematically searched for dose articulation studies. Preclinical experiments and adult clinical trials were classified based on the discovery pipeline and analyzed to determine which dose dimensions were articulated (time, scheduling or intensity) and how they were investigated (unidimensional vs multidimensional approach). Reporting of dose, safety and efficacy outcomes were summarized. The intervention description, risk of bias, and quality was appraised.

Results

We included 41 studies: 3 of preclinical dose preparation (93 rodents), 2 Phase I dose ranging (21 participants), 9 Phase IIA dose screening (198 participants), and 27 Phase IIB dose finding (1879 participants). All studies adopted a unidimensional approach. Time was the most frequent dimension investigated (53%), followed by intensity (29%), and scheduling (18%). Overall, 95% studies reported an efficacy outcome; however, only 65% reported dose and 45% reported safety. Across studies, 61% were at high risk of bias, and the average percentage reporting of intervention description and quality was 61% and 67%, respectively.

Conclusion

This review highlights a need to undertake more high-quality, early-phase studies that systematically articulate intervention doses from a multidimensional perspective in the field of behavioral motor stroke recovery. To address this gap, we need to invest in adapting early phase trial designs, especially Phase I, to support multidimensional dose articulation.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Stroke rehabilitation, Clinical trial, Translational medical research, Animal model, Neuroscience, Dosing


Mappa


© 2021  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 65 - N° 1

Articolo 101487- gennaio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Effective rehabilitation interventions and participation among people with multiple sclerosis: An overview of reviews
  • Anne-Mette Hedeager Momsen, Lisbeth Ørtenblad, Thomas Maribo
| Articolo seguente Articolo seguente
  • Equations for estimating the oxygen cost of walking in stroke patients: Systematic review
  • M. Compagnat, J.C. Daviet, A. Perrochon, J.Y. Salle, S. Mandigout

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.